Zymeworks (NYSE:ZYME), Inc. (NYSE:ZYME) is a clinical-stage biopharmaceutical company headquartered in Vancouver, Canada, with additional operations in the United States. Founded in 2003, Zymeworks focuses on the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company leverages an integrated technology engine to advance novel antibody-based therapies targeting a wide range of diseases, including oncology, immunology and women’s health conditions.
At the core of Zymeworks’ platform is its Azymetric™ bispecific antibody technology, which enables precise targeting of two distinct epitopes for enhanced therapeutic activity. The company also employs the AlbuCORE™ half-life extension technology to improve pharmacokinetics and dosing convenience. These proprietary platforms are complemented by advanced protein engineering capabilities that optimize stability, specificity and manufacturability of drug candidates.
Zymeworks has built a diversified pipeline comprising internally developed assets and partnered programs. Key clinical candidates include ZW25, a bispecific antibody targeting HER2-positive cancers, and ZW49, an antibody–drug conjugate designed for targeted tumor cell killing. Beyond its in-house portfolio, Zymeworks collaborates with leading pharmaceutical companies to co-develop and license therapeutic candidates, reflecting its commitment to strategic partnerships that accelerate innovation and broaden global patient access.
The company is led by an experienced management team with deep expertise in biotechnology research and biopharmaceutical commercialization. Zymeworks’ leadership emphasizes rigorous clinical development, scalable manufacturing and strong regulatory engagement to advance its pipeline efficiently. Serving patients worldwide, Zymeworks continues to expand its research footprint and strengthen collaborations aimed at delivering transformative therapies across multiple therapeutic areas.
